Obesity
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
A box of Ozempic sits on a table in North Tyneside, Britain, Oct. 31, 2023. Lee Smith | Reuters Danish pharmaceutical giant Novo Nordisk said Wednesday it is trimming its growth expectations for its leading obesity and diabetes treatments as competition intensifies and pricing pressures mount in the weight loss market. Net profit for the […]
Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]
Read More
Eli Lilly shares surge on new obesity pill data. What it means for the stock from here
Eli Lilly is tightening its grip on the lucrative weight-loss market as it moves into a new, more convenient phase that promises to broaden the appeal of its breakthrough drugs. The news Club name Lilly said its daily obesity pill was successful in a late-stage trial for Type 2 diabetes — sending shares soaring more […]
Read More
The weight-loss drug boom has become one of the internet’s biggest scams
A production line of Wegovy injection pens for the Asian market at the Novo Nordisk A/S pharmaceutical manufacturing facility in Hillerod, Denmark, on Wednesday, Nov. 27, 2024. Bloomberg | Bloomberg | Getty Images One interpretation of the law of supply and demand is that when demand outstrips supply, scammers get busy. That’s certainly the case […]
Read More
Novo Nordisk’s diabetes drug Ozempic may reduce the risk of Alzheimer’s disease, study says
Steve Christo – Corbis | Corbis News | Getty Images Novo Nordisk‘s blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer’s disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday. Semaglutide, the active ingredient in Ozempic, was associated with a 40% to 70% lower risk […]
Read More
Ozempic is driving up the cost of your health care, whether you can get your hands on it or not
About 165 million Americans rely on employer-sponsored health insurance and yet, workers may still not get the coverage they want — particularly when it comes to drugs like Wegovy and Novo Nordisk’s diabetes drug Ozempic. One in three employees are looking for more resources to combat obesity, according to a recent report by consulting firm Gallagher. […]
Read More
Port strike fallout: Blockbuster weight-loss drug supply from Wegovy to Ozempic, Mounjaro, Zepbound, caught up in East Coast trade shutdown
An Eli Lilly & Co. Zepbound injection pen, March 28, 2024. Bloomberg | Bloomberg | Getty Images As a port strike stretching from New England to Texas halted nearly half of all trade coming into the U.S., customs data shows that critical medical devices and drug components for the booming, expensive weight-loss and diabetes drugs […]
Read More
We’re taking a nearly 300% profit on a hot drug stock — adhering to an investing rule to live by
Shortly after the opening bell, we’ll be selling 10 shares of Eli Lilly at roughly $958 each. Following Monday’s trade, Jim Cramer’s Charitable Trust will own 100 shares of LLY, decreasing its weighting to 2.85% from about 3.13%. Now that we are no longer restricted, we are selling some Eli Lilly shares. We downgraded Lilly […]
Read More
CNBC Daily Open: A ‘crazy’ summer
Traders work on the floor of the New York Stock Exchange during morning trading on August 20, 2024 in New York City. Michael M. Santiago | Getty Images This report is from today’s CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no […]
Read More
CNBC Daily Open: ‘Crazy’ summer
Traders work on the floor of the New York Stock Exchange during morning trading on Aug. 20, 2024. Michael M. Santiago | Getty Images This report is from today’s CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. […]
Read More